Developing vaccines against EBV-associated diseases

Moss, Denis J., Burrows, Scott R. and Khanna, Rajiv (2005). Developing vaccines against EBV-associated diseases. In Erle S. Robertson (Ed.), Epstein-Barr Virus (pp. 651-667) Wymondham, England: Caister Academic Press.

Author Moss, Denis J.
Burrows, Scott R.
Khanna, Rajiv
Title of chapter Developing vaccines against EBV-associated diseases
Title of book Epstein-Barr Virus
Place of Publication Wymondham, England
Publisher Caister Academic Press
Publication Year 2005
Sub-type Research book chapter (original research)
ISBN 1904455034
Editor Erle S. Robertson
Chapter number 30
Start page 651
End page 667
Total pages 17
Total chapters 33
Language eng
Subjects 320402 Medical Virology
320400 Medical Microbiology
110704 Cellular Immunology
Abstract/Summary The past ten years have seen a dramatic accumulation of insights into the biology, immunology and virology of EBV so that for the first time rational vaccine development can begin. Thus the targets molecules present on latency I, II and III diseases have been well defined and the relative importance of both the cellular and the humoral responses are understood at least in the broad sense. Several vaccine trials towards infectious mononucleosis (IM) and post-transplant lymphoproliferative disease (PTLD) have been conducted and others are planned. While formulating vaccines for nasopharyngeal carcinoma (NPC) and Hodgkin's lymphoma (HL) are more speculative, there is good reason to believe that formulations encompassing cytotoxic T cell (CTL) epitopes encoded by LMP1 and LMP2 should have therapeutic benefit. On the other hand, there is little prospect for a vaccine to reverse the rapid growth of Burkitt's lymphoma.
Q-Index Code B1

Version Filter Type
Citation counts: Google Scholar Search Google Scholar
Created: Wed, 21 Jan 2009, 09:20:36 EST by Ms Julie Anne Hansen on behalf of Faculty Of Health Sciences